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Editorial Comment 
Transdermal Nitroglycerin* 
C. RICHARD CONTI, MD, FACC 
Gainesville, Florida 
Topical nitroglycerin. This agent was first introduced for 
the treatment of angina pectoris in 1955 but at that time it did 
not receive widespread clinical application. The method of 
delivery was developed to provide sustained gradual absorp- 
tion as a prophylactic agent for the prevention of angina 
pectoris. The first form of topical nitroglycerin was an 
ointment. This formulation enjoyed a revival as a therapeutic 
agent in the 197Os, when it was found to be especially useful 
for patients with unstable or nocturnal angina. 
In 1978 we investigated the effect of this formulation on 
systolic and diastolic pressure, heart rate and end-diastolic 
dimension as measured by M-mode echocardiography in 22 
patients with recurrent angina and proved coronary artery 
disease (1). The effects of sublingual nitroglycerin and nitro- 
glycerin ointment were compared. A typical response to 
sublingual nitroglycerin was a slight increase in heart rate, a 
slight decrease in blood pressure and a striking decrease in 
the end-diastolic diameter that began within the first 15 min 
of administration of the drug and persisted for <l h. In 
contrast, topical nitroglycerin produced in these same mea- 
surements a gradual change, that increased for a period of up 
to 1 h and was maintained for up to 4 h. 
Plasma drug levels obtained with 2% nitroglycerin oint- 
ment applied several times daily have been shown to be 
comparable with those achieved after sublingual and intra- 
venous nitroglycerin administration (2). Plasma levels ob- 
tained after application of nitroglycerin patches in most 
cases appear to be lower than those obtained with ointment 
or sublingual administration. 
Nitrate tolerance. In clinical practice, the problem of 
nitrate tolerance and nitrate dependence does not seem to be 
important. Perhaps this is partly related to the intermittent 
administration of the drug by the sublingual or oral route. 
Until recently, nitrates have been administered every 4 to 8 
h and in many instances are not administered throughout the 
night during sleep. Thus it is unlikely that most patients who 
are receiving nitrates in this dosing schedule develop steady 
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state plasma nitrate levels, and levels may decrease to zero 
or close to it. Subsequent drug administration would begin 
with either a low or absent plasma level of nitrates. Many 
investigators have shown that the transdermal nitroglycerin 
patches provide a constant nitrate plasma level over a 24 h 
period or for as long as the patch is applied. Thus patients 
receiving this form of nitroglycerin would very likely de- 
velop nitrate tolerance in a short period of time. 
Present study. Waters and colleagues (3), in this issue of 
the Journal, have questioned the efficacy of continuous and 
intermittent nitroglycerin patches (10 mg/day) in a random- 
ized placebo-controlled trial in 36 patients with stable angina 
and reproducible exercise-induced ST segment depression. 
Patients had continuous application of nitroglycerin for 
either 18 or 14 h/day. Results of the study by Waters et al. 
indicate that although some patients did seem to benefit from 
use of transdermal patches, the majority did not. In addition, 
there were a large number of side effects, principally head- 
ache, that made treatment less than optimal. Perhaps the 
frequency of headache can be explained by dilation of the 
cerebral veins because low dose nitrates preferentially dilate 
venous vessels. However, this latter point is only specula- 
tion. 
These investigators, who are well known in the area of 
ischemic heart disease, have performed a careful study of 
the efficacy of continuous and intermittent treatment with 
nitroglycerin patches. I agree with their assessment that the 
absence of improvement in their patients may be partially 
explained by the fact that exercise tests were done 12 to 18 
h after patch application. Others who have reported success 
have performed the exercise soon after patch application. It 
is unlikely that performing exercise tests 2 to 4 h after patch 
application would produce detrimental results due of toler- 
ance. 
The investigators indicate that a “postmarketing surveil- 
lance study” of 2,461 patients indicated that a 5 mg/day 
patch was judged effective in 80.6% with 70.5% experiencing 
no side effects. I share their concern about the scientific 
value of that observation. I suspect that patients reported in 
“postmarketing surveillance studies” were not treated 
solely with transderm nitroglycerin patches but rather with 
the usual multiple drugs that are currently in vogue to treat 
patients with angina pectoris. In my patients with symptoms 
of ischemic heart disease, I have always found it valuable to 
use nitrates as part of their medical treatment program. 
However, I cannot recall one patient whom I have treated 
only with transdermal nitrates. 
Clinical implications. When nitrates are combined with 
other antianginal agents, the problem of nitrate tolerance 
may be masked by the antianginal effects of the other drug. 
I have always been a strong advocate of nitrate therapy; 
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however, I prefer to use the drug in dosing schedules in 
which the nitrate level rises and falls rather than maintaining 
a constant blood level. Ideally, prophylactic therapy with 
nitrates should be tailored to the individual patient’s clinical 
presentation. For example. if myocardial ischemia occurs 
only in the morning, then prophylactic nitrate therapy should 
be used then and not throughout the day. Many patients 
have such angina1 patterns. I find it difficult to rationalize 24 
h/day nitrate therapy in these patients. 
Economic implications. This study and those like it may 
have tremendous economic implications because the use of 
transdermal patches seems to be a common phenomenon, at 
least in the United States. It seems to me that if patches are 
to be used, they should be applied for short periods of time, 
such as 2 to 4 h. Current transdermal patches are too 
expensive to be applied in this fashion. Perhaps the manu- 
facturers should consider making smaller patches at a price 
that is acceptable to the patient consumer. 
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